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OBJECTIVE—We report here genotyping data and type 1
diabetes association analyses for HLA class I loci (A, B, and C) on
1,753 multiplex pedigrees from the Type 1 Diabetes Genetics
Consortium (T1DGC), a large international collaborative study.
RESEARCH DESIGN AND METHODS—Complete eight-locus
HLA genotyping data were generated. Expected patient class I
(HLA-A, -B, and -C) allele frequencies were calculated, based on
linkage disequilibrium (LD) patterns with observed HLA class II
DRB1-DQA1-DQB1 haplotype frequencies. Expected frequencies
were compared to observed allele frequencies in patients.
RESULTS—Signiﬁcant type 1 diabetes associations were ob-
served at all class I HLA loci. After accounting for LD with HLA
class II, the most signiﬁcantly type 1 diabetes–associated alleles
were B*5701 (odds ratio 0.19; P  4  10
11) and B*3906 (10.31;
P  4  10
10). Other signiﬁcantly type 1 diabetes–associated
alleles included A*2402, A*0201, B*1801, and C*0501 (predispos-
ing) and A*1101, A*3201, A*6601, B*0702, B*4403, B*3502,
C*1601, and C*0401 (protective). Some alleles, notably B*3906,
appear to modulate the risk of all DRB1-DQA1-DQB1 haplotypes
on which they reside, suggesting a class I effect that is indepen-
dent of class II. Other class I type 1 diabetes associations appear
to be speciﬁc to individual class II haplotypes. Some apparent
associations (e.g., C*1601) could be attributed to strong LD to
another class I susceptibility locus (B*4403).
CONCLUSIONS—These data indicate that HLA class I alleles,
in addition to and independently from HLA class II alleles, are
associated with type 1 diabetes. Diabetes 59:2972–2979, 2010
T
ype 1 diabetes is an autoimmune disease char-
acterized by progressive T-cell–mediated de-
struction of the pancreatic -cells. Both genetic
and environmental factors are involved in dis-
ease susceptibility; the major genetic susceptibility deter-
minants are the highly polymorphic HLA loci on
chromosome 6p21—more speciﬁcally the class II loci,
HLA-DRB1, HLA-DQB1/DQA1 (see the study by Erlich et
al. [1] and references therein), and, to a lesser extent,
HLA-DPB1/DPA1 (2–6). These genes, however, cannot
completely explain the association between type 1 diabe-
tes and the HLA region. Several studies have shown that
HLA class I genes (A, B, and C) are associated with type 1
diabetes (7–11). Products of the HLA class I genes bind
and present peptide antigens. The HLA class I/peptide
antigen complexes function both in shaping the T-cell
repertoire in the thymus and in initiating antigen-speciﬁc
T-cell–mediated cytotoxicity, providing a plausible immu-
nological rationale to explain the genetic association. The
extremely high linkage disequilibrium (LD) within the HLA
region, combined with the strong susceptibility effects of
the HLA DR- and DQ-encoding loci, can confound associ-
ation studies of any loci in the region. Thus, apparent
susceptibility effects of HLA class I alleles may, in some
cases, be attributable to their presence on highly protec-
tive or predisposing HLA DRB1-DQA1-DQB1 haplotypes.
Compared with the hundreds of studies of HLA class II
association with type 1 diabetes, only a handful of reports
focus on HLA class I and type 1 diabetes (7–12), and only
a subset of these include molecular genotyping and con-
sideration of LD with class II in association analyses.
Some alleles have appeared consistently associated with
type 1 diabetes both at the serologic and allele level,
including A*24(02) and B*39(06), with and without condi-
tioning on DR-DQ. HLA class I loci are extremely polymor-
phic, with a total of 2,893 alleles assigned for the three loci
as of October 2009. Thus, large sample sizes are crucial to
generate sufﬁcient class I data for adequately powered
disease association studies. The Type 1 Diabetes Genetics
Consortium (T1DGC) is an international collaborative
project that has ascertained the largest set of multiplex
type 1 diabetes families in existence for the study of the
genetic basis of type 1 diabetes susceptibility. All samples
collected by the T1DGC are genotyped at all classical HLA
loci (DRB1, DQA1, DQB1, DPA1, DPB1, A, B, and C)a s
well as for single nucleotide polymorphisms (SNPs) in the
insulin and CTLA4 genes that have repeatedly been shown
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T1DGC collection have been genotyped for candidate gene
SNPs reported to be associated with type 1 diabetes (the
“Rapid Response” project), genome-wide microsatellites,
and genome-wide SNPs (www.T1DGC.org).
RESEARCH DESIGN AND METHODS
The subjects included in this dataset were comprised of newly collected
samples and samples from previously existing collections. The sample set
tested included 1,753 Caucasian multiplex type 1 diabetes families compiled
from four existing collections (DAN  Denmark; HBDI  Human Biological
Data Interchange; JOS  Joslin Diabetes Center; SAR  Sardinia) and newly
collected from four T1DGC networks (AP  Asia Paciﬁc network; EUR 
European network; NA  North American network; UK  United Kingdom
network). The total number of affected offspring is 3,577. All samples were
collected with appropriate informed consent, and all collections were done
with the approval of the appropriate institutional review board at the
collection sites (www.T1DGC.org). Table 1 includes the descriptive statistics
for the collection.
Genotyping methods. All samples, including existing collections, were
genotyped using standardized protocols, including inter- and intra-lab quality
control procedures, at one of three T1DGC HLA genotyping centers (Oakland
and Alameda, CA; Melbourne, Australia; and Malmo ¨, Sweden) (1). High-
resolution HLA genotyping was performed with a PCR-based sequence-
speciﬁc oligonucleotide probe system. Brieﬂy, a series of oligonucleotide
probes, corresponding to known polymorphic sequence motifs in the HLA
genes, was immobilized onto a backed nylon membrane to create a “linear
array.” Relevant polymorphic exons (exon 2 for HLA class II genes; exons 2
and 3 for HLA class I genes) were ampliﬁed with biotinylated PCR primers.
The PCR product was denatured and subsequently hybridized to the appro-
priate linear array. After hybridization and wash, arrays were incubated with
streptavidin-horseradish peroxidase, followed by the chromogenic substrate
tetramethylbenzidine. Images were created by placing the arrays on a ﬂatbed
scanner, and probe intensities were measured as pixel values with a propri-
etary genotyping software called StripScan. Preliminary genotypes were
determined with StripScan, and then data from StripScan were imported into
Sequence Compilation and Rearrangement Evaluation (SCORE) software (13)
for ﬁnal genotyping calling and export of data to the coordinating center.
Genotyping was completed for each sample for each locus (i.e., no failed
typing). All primary probe-binding data were reported to the coordinating
center; allele calls were reported at four-digit resolution. We note here that,
because of the extreme polymorphism of the HLA genes, some alleles were
indistinguishable from others in our genotyping assay. Alleles exhibiting type
1 diabetes association after adjustment of the data for LD with HLA class II
DR-DQ–encoding haplotypes, or that modify the risk for one of the risk
haplotypes in our “relative odds ratio” analysis, are listed here with the
alternative alleles that are consistent with the probe binding pattern for the
called allele: A*0101 (0104N, 0108, 0109, 0111N); A*0201 (0209, 0222, 0225,
0229, 0230, 0231, 0232N, 0233, 0242, 0243N, 0253N, 0259, 0260, 0264, 0266,
0267, 0268, 0270, 0271, 0274, 0275, 0277, 0282N, 0283N, 0285, 0286); A*1101
(1105, 1107, 1109, 1112, 1113, 1115, 1121N, 1122, 1123); A*2402 (2409N, 2411N,
2420, 2423, 2425, 2426, 2427, 2429, 2430, 2431, 2434, 2435, 2437, 2439, 2440N,
2443, 2447, 2448N, 2449, 2452, 2453); A*3201 (3205, 3208, 3209); A*6601 (no
ambiguous alleles); B*0702 (0710, 0721, 0722, 0723, 0730, 0735); B*1801 (1803,
1805, 1808, 1815, 1817N, 1820); B*3502 (3504, 3509); B*3906 (no ambiguous
alleles); B*4403 (4413, 4432, 4436, 4438); B*5701 (B*5706); C*0401 (0405,
0409N, 0412); C*0501 (0503, 0505, 0507N, 0509, 0510); C*0701 (0706, 0716,
0718, 0720, 0724, 0727); and C*1601 (no ambiguous alleles). In this article, we
also refer to general serologic nomenclature, e.g., DR3, DR4, DR1, and DR8, to
refer to haplotypes bearing the DRB1*03xx, DRB1*04xx, DRB1*01xx, and
DRB1*08xx alleles, respectively. The term DR2 is used in this article to refer
to the most common, and highly type 1 diabetes protective, Caucasian DR2
haplotype (DRB1*1501-DQA1*0102-DQB1*0602).
Statistical analysis. Control haplotypes were determined based on the
affected family-based control (AFBAC) method (14). The transmission of
overall haplotypes at all typed loci (DPA1, DPB1, DRB1, DQA1, DQB1,
HLA-C, HLA-B, HLA-A) was used to determine AFBAC haplotypes; in this
case, those parental haplotypes never transmitted to the affected sib-pair.
Because only the proband from each family is used in the analyses, this
approach does not introduce a bias because of the nonindependence between
sibs.
Adjustment for LD with DRB1-DQB1 haplotypes. The expected allele
frequencies were computed, given known HLA DR-DQ primary associations
with type 1 diabetes and their observed haplotype frequencies in both patients
and controls. Brieﬂy, the null hypothesis (H0) is that class I allele frequencies
will differ between patients and controls 1) because of LD between the class
I loci and DRB1-DQB1 and 2) due to chance (sampling), thus implying that
class I loci are neutral relative to disease predisposition.
Under H0, the expected allele frequencies at a given class I allele can be
computed using the equation derived by Thomson (15)
qexp classIj  pclassIj 
i
K
Dij
qclassIIi
pclassIIi
where Dij denotes the pair-wise LD coefﬁcient between the ith DRB1-DQB1
haplotype and the jth class I allele in the control sample, q denotes the allele
or haplotype frequency in patients, p denotes the frequency in the AFBAC, and
qexp denotes the expected frequency in patients under the assumption of no
involvement of the class I allele in disease. This method relies on sampling
estimates of pair-wise LD between a putative second disease locus and the
DRB1-DQB1 haplotypes and on the proband and control frequencies derived
from the samples under study. Thus, there will be a sampling error associated
with the computed value for expected class I alleles. The larger the control
sample, the smaller this error would be. This has been taken into account in
the statistical tests carried out as previously described (7). Given the large
number of classical loci haplotypes and the error that rare haplotypes could
introduce, only haplotypes at the susceptibility loci with an average frequency
of 0.5% in combined cases and controls were used. Moreover, only class
II–class I haplotypes where the expected frequency in controls in the absence
of LD would be 0.05% were included in the analysis.
In addition, for speciﬁc HLA-B (B*4403) and HLA-C (C*1601) associations,
we tested whether the association was due to the 4403-1601 haplotype or to
only one of the loci. Under the null hypothesis that the association seen was
due to, for example, only B*4403, we expect the frequencies of C*1601 alleles
on these haplotypes to be the same in transmitted and nontransmitted
haplotypes. This analysis can be extended to include additional predisposition
effects from other classical HLA loci (in this case, DRB1*0701 HLA-B*4403
haplotypes). If the allele under study (C*1601) has no effect on type 1 diabetes
risk, the transmission proportions of this allele should be the same, condi-
TABLE 1
Descriptive statistics of sample studied
Cohort Origin Collection Pedigrees
Type 1
diabetic
sibs per
pedigree
Type 1
diabetic
offspring
in cohort
Type 1
diabetic
male
Type 1
diabetic
female Male (%)
Age of
onset
(years)
Age of onset
(range)
AP Asia Paciﬁc New 150 2.02  0.24 303 153 150 50.50 10.06  7.43 0–37
DAN Denmark Extant 94 2.05  0.33 194 105 90 54.12 11.73  8.30 0.8–49
EUR Europe New 470 2.01  0.10 945 513 432 54.29 10.76  7.26 1–35
HBDI U.S. Extant 416 2.10  0.42 879 471 410 53.58 11.90  8.22 0.8–50
JOS U.S. Extant 57 2.14  0.58 122 60 62 49.18 11.22  7.31 1–31
NA U.S. New 407 2.01  0.21 819 435 384 53.11 8.763  6.45 0–34
SAR Sardinia Extant 52 1.98  0.14 101 47 54 46.53 12.34  7.90 0.7–34
UK U.K. New 107 2.00  0.13 214 97 117 45.33 7.65  4.48 0–23
Total 1,753 2.03  0.28 3,577 1,881 1,699 52.59 10.44  7.41 0–50
Data are means  SD unless otherwise indicated.
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HLA class I allele frequencies in 3,506 chromosomes from 1,753
type 1 diabetic probands and 1,585 affected family-based control
chromosomes
Allele
Type 1
diabetes
(n)
AFBAC
(n) P
A*0101 17.7 (621) 16.1 (256) 0.214
A*0102 0.1 (4) 0 (0) 0.179
A*0103 0 (0) 0.1 (2) 0.035
A*0201 30.6 (1,074) 27.6 (438) 0.069
A*0202 0.2 (8) 0 (0) 0.057
A*0205 2.1 (73) 1.2 (19) 0.030
A*0206 0.3 (9) 0.2 (3) 0.646
A*0211 0 (1) 0 (0) 0.501
A*0220 0 (0) 0.1 (1) 0.137
A*0234 0 (0) 0.1 (1) 0.137
A*0235 0 (0) 0.1 (1) 0.137
A*0301 11.9 (417) 13.1 (207) 0.271
A*0302 0.5 (16) 0.3 (4) 0.282
A*0305 0 (0) 0.1 (1) 0.137
A*1101 3.4 (119) 6.9 (109) 5.E-08
A*1105 0 (0) 0.1 (1) 0.137
A*2301 1.2 (43) 1.8 (29) 0.094
A*2401 0 (0) 0.1 (1) 0.137
A*2402 11.3 (396) 7.8 (123) 2.E-04
A*2403 0.3 (10) 0.1 (1) 0.114
A*2501 2.3 (80) 2.6 (42) 0.432
A*2601 2.6 (90) 2.8 (44) 0.671
A*2607 0 (0) 0.1 (1) 0.137
A*2608 0.1 (2) 0 (0) 0.342
A*2901 0.3 (12) 0.4 (6) 0.840
A*2902 2.3 (80) 3.4 (54) 0.022
A*3001 0.7 (25) 1.1 (17) 0.191
A*3002 3.3 (117) 1.7 (27) 0.001
A*3004 0.1 (2) 0.1 (1) 0.934
A*3010 0 (1) 0 (0) 0.501
A*3101 2.1 (74) 1.9 (30) 0.614
A*3201 2.1 (73) 4.2 (67) 2.E-05
A*3204 0 (0) 0.1 (1) 0.137
A*3301 0.8 (27) 1 (16) 0.390
A*3303 0.4 (14) 0.3 (5) 0.650
A*3402 0.2 (6) 0.1 (1) 0.336
A*3601 0 (1) 0.1 (2) 0.184
A*6601 0.1 (3) 0.6 (10) 4.E-04
A*6602 0.1 (2) 0 (0) 0.342
A*6801 2.6 (91) 2.7 (43) 0.811
A*6802 0.4 (14) 1.3 (20) 5.E-04
A*6901 0 (0) 0.1 (1) 0.137
A*7401 0 (0) 0.1 (1) 0.137
A*8001 0 (1) 0 (0) 0.501
B*0702 7 (244) 14.7 (233) 7.E-17
B*0704 0 (0) 0.1 (1) 0.137
B*0705 0.7 (26) 0.3 (4) 0.035
B*0707 0 (0) 0.1 (1) 0.137
B*0801 21 (735) 10.9 (173) 4.E-15
B*0809 0 (0) 0.1 (1) 0.137
B*1302 1.8 (64) 2 (31) 0.752
B*1401 0.2 (8) 0.6 (9) 0.052
B*1402 1.7 (60) 2.6 (41) 0.040
B*1501 12.3 (432) 4.5 (71) 2.E-16
B*1502 0.1 (2) 0 (0) 0.342
B*1503 0.1 (5) 0.1 (1) 0.444
B*1507 0.1 (3) 0 (0) 0.244
B*1508 0 (1) 0 (0) 0.501
B*1509 0.1 (2) 0.1 (1) 0.934
Continued
TABLE 2
Continued
Allele
Type 1
diabetes
(n)
AFBAC
(n) P
B*1510 0.1 (4) 0 (0) 0.179
B*1515 0 (1) 0 (0) 0.501
B*1516 0 (1) 0.1 (1) 0.564
B*1517 0.4 (15) 0.3 (4) 0.343
B*1518 0.2 (6) 0.3 (5) 0.305
B*1524 0.1 (3) 0 (0) 0.244
B*1525 0 (0) 0.1 (1) 0.137
B*1537 0 (1) 0 (0) 0.501
B*1571 0 (0) 0.1 (1) 0.137
B*1573 0 (0) 0.1 (1) 0.137
B*1801 10.2 (357) 6.3 (100) 2.E-05
B*1812 0 (1) 0 (0) 0.501
B*2701 0 (0) 0.1 (1) 0.137
B*2702 0.3 (9) 0.4 (6) 0.458
B*2703 3.2 (113) 3.1 (49) 0.807
B*2707 0 (1) 0.1 (2) 0.184
B*3501 3.6 (126) 6.3 (100) 2.E-05
B*3502 0.3 (12) 1.5 (23) 1.E-05
B*3503 1.6 (56) 1.5 (23) 0.698
B*3508 0.3 (12) 0.5 (8) 0.392
B*3512 0 (0) 0.1 (1) 0.137
B*3701 0.7 (23) 1 (16) 0.182
B*3801 1.8 (63) 2.5 (40) 0.091
B*3901 1.2 (42) 1.2 (19) 0.998
B*3906 3.2 (112) 0.4 (7) 3.E-09
B*4001 5.6 (198) 4.4 (69) 0.062
B*4002 0.6 (20) 1.6 (25) 4.E-04
B*4006 0.1 (3) 0.2 (3) 0.318
B*4009 0 (1) 0 (0) 0.501
B*4014 0 (0) 0.1 (2) 0.035
B*4101 1 (34) 0.3 (4) 0.006
B*4102 0.1 (2) 0.4 (6) 0.007
B*4201 0 (1) 0 (0) 0.501
B*4202 0 (0) 0.1 (1) 0.137
B*4402 6 (210) 9 (143) 1.E-04
B*4403 2 (69) 5.7 (91) 2.E-12
B*4404 0 (0) 0.1 (1) 0.137
B*4405 0.2 (7) 0.1 (1) 0.255
B*4501 0.5 (17) 0.4 (7) 0.835
B*4701 0.3 (10) 0.4 (6) 0.582
B*4702 0 (1) 0 (0) 0.501
B*4801 0.1 (2) 0.1 (1) 0.934
B*4901 2.2 (77) 1.1 (17) 0.006
B*5001 2.1 (75) 1.2 (19) 0.022
B*5002 0.1 (2) 0.1 (1) 0.934
B*5101 3 (104) 4.2 (67) 0.023
B*5102 0 (0) 0.1 (1) 0.137
B*5105 0 (0) 0.1 (1) 0.137
B*5107 0 (1) 0.1 (1) 0.564
B*5108 0.1 (4) 0.1 (1) 0.591
B*5201 0.3 (12) 1.1 (18) 0.001
B*5301 0.1 (5) 0.5 (8) 0.018
B*5501 0.9 (30) 1.6 (26) 0.013
B*5601 0.6 (20) 0.6 (10) 0.795
B*5701 0.5 (19) 3.5 (56) 4.E-16
B*5703 0 (1) 0.3 (5) 0.006
B*5801 0.9 (31) 1.1 (18) 0.397
B*7301 0.3 (9) 0.1 (1) 0.149
B*8101 0 (1) 0 (0) 0.501
C*0102 2 (69) 3 (48) 0.021
Continued on facing page
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each family were used. Deviations from the random expectation were
assessed using a 
2 test where the total sum in the contingency table was
200, or a Fisher’s exact test otherwise. This methodological approach has
been described and discussed in detail elsewhere (16).
RESULTS
Frequency data for HLA-A, HLA-B, and HLA-C alleles in
probands (n  1,753) are shown in Table 2. Proband
frequencies were compared with allele frequencies from
AFBAC (15), which are alleles that are not transmitted
from parent to any affected child. We previously reported
HLA class I association data for families from the Human
Biological Data Interchange (HBDI) (7,9). The HBDI fam-
ilies were re-genotyped with high-resolution reagents and
are included as part of the T1DGC collection. We per-
formed association analyses on the T1DGC families who
were not from the HBDI and found that the results were
not signiﬁcantly different for the two groups. These data
are shown in supplementary Table 1, available in on online
appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0699/DC1.
Linkage disequilibrium. The HLA region exhibits some of
the strongest LD in the genome, and the strongest type 1
diabetes disease associations in the region have been well
established to come from the HLA class II genes encoding the
DR and DQ antigens. Thus, primary association data for HLA
region markers must be adjusted for LD with strongly
associated class II alleles. To adjust for LD to DR and DQ,
expected allele frequencies among patients are adjusted
mathematically to reﬂect the LD observed in the sample set
(15) and compared with the observed allele frequencies
among patients. Alleles that remain signiﬁcantly associated
with type 1 diabetes after adjustment for LD are shown in
Table 3. Association data for all alleles after LD adjustment
can be found in supplementary Table 2. After LD adjustment,
the two most strongly type 1 diabetes–associated alleles are
B*5701 (protective) and B*3906 (predisposing). For further
conﬁrmation, transmission disequilibrium testing (TDT)
analysis stratiﬁed by DRB1-DQB1 haplotype was per-
formed and showed signiﬁcant type 1 diabetes protection
for B*5701 on DRB1*0101-DQB1*0501 and DRB1*0301-
DQB1*0201 haplotypes and signiﬁcant type 1 diabetes risk
for B*3906 on DRB1*0101-DQB1*0501, DRB1*0301-
DQB1*0201, DRB1*0404-DQB1*0302, and DRB1*0801-
DQB1*0402 haplotypes (data not shown). Stratiﬁed TDT
analysis was also performed on A*2402 and showed signif-
icant type 1 diabetes risk on eight DRB1-DQB1 haplotypes,
including DRB1*0101-DQB1*0501, DRB1*0101-DQB1*0504,
DRB1*0301-DQB1*0201, DRB1*0401-DQB1*0302, DRB1*0404-
DQB1*0302, DRB1*0701-DQB1*0303, DRB1*0801-DQB1*0402,
and DRB1*1601-DQB1*0502 (data not shown). An overview
of LD for selected type 1 diabetes–associated class I alleles
is shown in Fig. 1. Type 1 diabetes–associated class II
allele groups, including DR3, DR4, DR1, DR8 (susceptible),
and DR2 (protective) are also included. As expected,
TABLE 2
Continued
Allele
Type 1
diabetes
(n)
AFBAC
(n) P
C*0202 3.9 (136) 4.4 (69) 0.435
C*0206 0 (1) 0.1 (1) 0.564
C*0302 0.3 (12) 0.4 (7) 0.591
C*0303 5.5 (194) 3.9 (62) 0.017
C*0304 13.5 (475) 6.6 (105) 1.E-11
C*0305 0.1 (3) 0 (0) 0.244
C*0314 0 (1) 0 (0) 0.501
C*0401 6 (212) 11.6 (184) 4.E-11
C*0403 0 (0) 0.1 (1) 0.137
C*0501 11.3 (397) 9.5 (150) 0.061
C*0602 5.9 (208) 8.4 (133) 0.002
C*0606 0 (1) 0 (0) 0.501
C*0701 25.7 (900) 15 (238) 1.E-13
C*0702 10.8 (378) 15.6 (247) 6.E-06
C*0704 1 (34) 1.9 (30) 0.007
C*0801 0.1 (5) 0.1 (2) 0.884
C*0802 1.9 (66) 3.2 (50) 0.005
C*1202 0.3 (12) 1.1 (17) 0.001
C*1203 5.7 (200) 6.4 (102) 0.322
C*1402 0.7 (25) 1.2 (19) 0.084
C*1502 1.4 (50) 2 (32) 0.123
C*1504 0.2 (8) 0.1 (2) 0.447
C*1505 0.8 (27) 0.3 (5) 0.058
C*1601 1.2 (43) 3.8 (60) 3.E-09
C*1602 0.5 (17) 0.2 (3) 0.119
C*1604 0.1 (4) 0.4 (6) 0.049
C*1701 0.8 (27) 0.7 (11) 0.771
C*1801 0 (1) 0.1 (1) 0.564
P values lower than 0.1 are shown in boldface type.
TABLE 3
HLA class I alleles signiﬁcantly different from expected values
when accounting for LD with DRB1-DQB1
Allele
Type 1
diabetes
observed
(%)
Type 1
diabetes
expected
(%)† OR (95% CI) P
A*0101 17.7 21.9 0.77 (0.66–0.88) 0.002
A*0201 30.6 24.7 1.35 (1.17–1.54) 3.E-04
A*1101 3.4 6.2 0.53 (0.40–0.70) 8.E-06
A*2402 11.4 7.0 1.71 (1.37–2.12) 5.E-06
A*3201 2.1 3.8 0.54 (0.37–0.75) 4.E-04
A*6601 0.1 0.6 0.16 (0.04–0.57) 9.E-04
A*6802 0.4 1.2 0.34 (0.17–0.69) 0.002
B*0702 7.0 11.4 0.58 (0.47–0.70) 3.E-07
B*0705 0.7 0.2 3.42 (1.11–10.5) 0.023
B*1501 12.3 9.4 1.36 (1.11–1.65) 0.004
B*1801 10.2 5.2 2.05 (1.59–2.61) 3.E-08
B*3501 3.6 4.9 0.72 (0.53–0.96) 0.028
B*3502 0.3 1.2 0.29 (0.14–0.60) 5.E-04
B*3906 3.2 0.3 10.31 (4.21–25.1) 4.E-10
B*4002 0.5 1.2 0.45 (0.23–0.84) 0.012
B*4101 1.0 0.2 4.49 (1.48–13.6) 0.004
B*4102 0.1 0.3 0.19 (0.03–0.96) 0.020
B*4403 1.9 4.5 0.42 (0.30–0.59) 4.E-07
B*4901 2.2 0.9 2.6 (1.45–4.63) 0.001
B*5001 2.1 1.0 2.27 (1.30–3.94) 0.003
B*5201 0.3 0.9 0.37 (0.17–0.80) 0.009
B*5301 0.1 0.4 0.33 (0.10–1.06) 0.055
B*5701 0.5 2.8 0.19 (0.11–0.32) 4.E-11
B*5703 0.0 0.3 0.11 (0.01–0.96) 0.013
C*0303 5.5 3.8 1.48 (1.10–1.99) 0.010
C*0401 6.0 9.3 0.63 (0.50–0.78) 6.E-05
C*0501 11.3 7.6 1.56 (1.26–1.93) 9.E-05
C*1202 0.3 0.9 0.39 (0.17–0.83) 0.014
C*1402 0.7 1.4 0.52 (0.29–0.93) 0.027
C*1505 0.8 0.3 2.78 (1.01–7.62) 0.039
C*1601 1.2 3.0 0.39 (0.25–0.58) 5.E-06
†Expected values calculated based on LD of class I alleles with
DR-DQ–encoding loci in this population.
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extended haplotype known as “A1-B8-DR3,” or simply
“8.1,” are in strong LD with each other. However, even
stronger LD was observed for the alleles B*4403 and
C*1601. Frequencies for both of these alleles were de-
creased in patients compared with controls (Table 2), and
this apparent protective effect remained even after adjust-
ment of the data to account for LD with DR and DQ (Table
3). These two alleles are in strong LD (r
2  49, Fig. 1);
thus, most haplotypes that contain one of these two alleles
contain the other as well, making distinction of effects of
individual alleles difﬁcult. The T1DGC has amassed such a
large collection of families that haplotypes containing one
or the other of these alleles were found. The data shown in
Table 4 suggest that the transmission proportion for
haplotypes carrying B*4403 does not differ signiﬁcantly
whether or not the haplotype carries C*1601 as well. On
the other hand, for haplotypes carrying C*1601, the trans-
mission proportion is lower when B*4403 is also included
on the haplotype. This difference did not reach statistical
signiﬁcance; however, comparison of these two alleles on
a single haplotype, DR7, was signiﬁcant. The transmission
proportion of DR7-B*4403-C*not1601 haplotypes is low
(10.99%), whereas transmission proportion for DR7-
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FIG. 1. LD diagram for selected HLA alleles. The r
2  100 value of LD between pairs of alleles is shown.
TABLE 4
Protective effect of C*1601 appears to be caused by LD with B*4403
DR HLA-B HLA-C Not trans Trans Trans proportion (%) P
All B*4403 All 282 118 29.50
All B*4403 C*1601 156 66 29.73
All B*4403 not C*1601 115 40 25.81 NS
All All C*1601 173 80 31.62
All B*4403 C*1601 156 66 29.73
All not B*4403 C*1601 17 14 45.16 0.13
DR7† B*4403 not C*1601 81 10 10.99
DR7 not B*4403 C*1601 3 4 57.14 0.0074
DR7 B*4403 C*1601 124 36 22.50
DR7 B*4403 not C*1601 81 10 10.99 0.023
DR7 B*4403 C*1601 124 36 22.50
DR7 not B*4403 C*1601 3 4 57.14 0.036
†DRB1*0701 DQB1*0201.
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ent protective effect (P value for difference 0.0074). The
number of DR7 haplotypes carrying C*1601 without
B*4403 is small (n  7 total, three transmitted and four not
transmitted), so these data should be interpreted with
caution. Other haplotype combinations were examined,
including B*1501-C*0303, which suggested that, on DR3
haplotypes, the predisposing effect of B*1501-C*0303 may
be attributable to the C*0303 or something in LD with it,
rather than to the B*1501 allele; however, the result did
not reach statistical signiﬁcance (P  0.069, data not
shown). Data were too sparse for meaningful analysis of
any other class I allele combinations. This result under-
scores both the complexity of statistical analysis of indi-
vidual HLA alleles in this region of strong LD and the need
for very large datasets to distinguish true susceptibility
effects from apparent effects attributable to LD of a given
allele with a second allele with strong type 1 diabetes
susceptibility.
Disease susceptibility effects in multiple DR-DQ hap-
lotypes. Even when an HLA allele exhibits an apparent
strong effect on type 1 diabetes susceptibility, the abun-
dance of both classic HLA loci and other immunologically
relevant loci, such as TNF, in the region can limit the
conﬁdence that an apparent type 1 diabetes association is
directly due to the locus under investigation. One criterion
that can help evaluate whether a particular HLA allele
itself is affecting type 1 diabetes susceptibility is to see if
the effect of the allele is consistent across multiple DR-DQ
haplotypes. DR3 haplotypes (containing DRB1*0301) and
DR4 haplotypes (with DRB1*04 alleles, except for 0403
and 0406, and carrying DQB1*0302) are established as the
most highly type 1 diabetes–predisposing haplotypes in
Caucasians, and the common DR2 haplotype DRB1*1501-
DQB1*0602, is the most strongly protective. We examined
the effects of the HLA-A, HLA-B, and HLA-C alleles in the
context of these speciﬁc haplotypes, as well as on the
more moderately predisposing DR1 and DR8 haplotypes,
to look for susceptibility effects that were seen in more
than one haplotypic context and that, when signiﬁcantly
associated, always had the same effect qualitatively (i.e.,
always protective, or always predisposing). For each of
the ﬁve DR haplotypes being tested (DR3, DR4, DR1, DR8,
and DR2), we compared haplotypes carrying a given class
I allele to that haplotype carrying any allele at the locus in
question. To determine the value referred to here as the
“relative odds ratio,” we arbitrarily set the odds ratio (OR)
for each tested DR-DQ haplotype, regardless of class I
(e.g., “DR3-any,” “DR4-any,” etc.), to 1.0 and compared
individual haplotypes with given class I alleles to the “any”
baseline to generate a relative OR. In other words, the total
of any of the tested haplotypes (e.g., DR4, DR1, etc.)
provides the baseline, set at a value of 1.0, to which
haplotypes of each category with particular class I alleles
(e.g., DR4-B*3906, DR1*B*5701) can be compared. Thus,
although the absolute OR for DR3-A*0101 is 1.69, the
relative OR for DR3-A*0101, compared with the entire set
of DR3 haplotypes (DR3-any), is 0.69. This means that a
DR3 haplotype carrying A*0101 is less predisposing than
the average of all DR3 haplotypes, even though DR3-
A*0101 is still predisposing overall. A summary of alleles
with signiﬁcant relative OR in multiple DR haplotypes is
shown in Table 5. Values are included for any allele that
showed a signiﬁcant relative OR on more than one of our
selected type 1 diabetes–associated haplotypes. Also, the
direction of the effect, i.e., protective (OR 1) or suscep-
tible (OR 1), was compared for consistency among
haplotypes. The most striking example of an effect that
was seen consistently in multiple haplotypic contexts is
that of B*3906, which signiﬁcantly increases the risk of
four of ﬁve tested haplotypes and shows a nonsigniﬁcant
trend toward increased risk in the remaining one (DR3).
DR2-B*3906 haplotypes, while still type 1 diabetes protec-
tive overall, are signiﬁcantly less type 1 diabetes protective
than DR2 haplotypes with an unspeciﬁed HLA-B allele.
This difference argues that the type 1 diabetes predispos-
ing effect is coming from the HLA-B allele itself, rather
than from an unidentiﬁed locus in LD with B*3906 and is
consistent with other studies (10,11). We note here that
the allele B*5701, which exhibited the strongest type 1
diabetes association in the LD-adjusted data, did not
signiﬁcantly affect any of the DR haplotypes tested; how-
ever, for all predisposing DR haplotypes tested, all relative
ORs for B*5701 on predisposing haplotypes were 1.
These relative ORs, including DR3-B*5701 (OR 0.43, 95%
CI 0.17–1.05), DR4-B*5701 (0.57, 0.22–1.42), DR8-B*5701
(0.22, 0.00–4.94), and DR1-B*5701 (0.16, 0.02–1.27), while
individually not reaching statistical signiﬁcance, were all
suggestive of a protective effect of the B*5701 allele. A
larger sample size may be required to demonstrate signif-
icant haplotype-speciﬁc effects for this allele.
In our “relative OR” analysis for speciﬁc haplotypes, ten
other alleles exhibited a signiﬁcant risk modulation for at
least two of the ﬁve haplotypes tested. Four of these
(A*6801, B*3501, B*4403, and C*0501) had opposite effects
on different haplotypes, suggesting that the observed
effects represent either haplotype-speciﬁc effects or type 1
error. In addition to B*3906, six additional alleles had risk
effects of the same type on more than one haplotype.
These include the predisposing alleles A*2402, B*1801, and
C*0702 and the protective alleles A*0101, A*3201, and
C*0701.
DISCUSSION
Unraveling the effects of individual HLA class I alleles on
type 1 diabetes susceptibility requires taking into account
both the allele itself and its context (LD pattern). The
results presented here show apparent class I associations
that are speciﬁc to a single haplotype and associations that
can be accounted for by LD to another class I allele.
However, these data also show associations that are
consistent across multiple DR-DQ haplotypes, suggesting
that they represent true independent disease-associated
alleles.
One method of decreasing the complexity of HLA class
I disease association data are to bin alleles into two-digit
resolution, based on serologic reactivity, which can in-
crease statistical power by decreasing sparseness. How-
ever, not all alleles within a serologic category necessarily
have the same effect on type 1 diabetes susceptibility. For
example, a study of Filipino type 1 diabetic patients and
control subjects showed that A*2407 appears protective
for type 1 diabetes, whereas the closely related A*2402
allele is highly predisposing (12). Two HLA-B alleles,
B*4402 and B*4403, that differ at only a single encoded
amino acid residue have been shown to stimulate strong
allogeneic responses in hematopoietic transplant (17). In
the T1DGC dataset presented here, B*4402 appears neu-
tral for type 1 diabetes risk, whereas B*4403 is highly
protective (supplemental Table 2). Thus, analysis of indi-
vidual alleles at the four-digit level is preferable and can
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represents, to our knowledge, the largest existing dataset
of its kind and includes high-resolution genotyping results
reported at four-digit resolution.
Even when genotyping resolution is at the allele level,
the effects of any given locus in the HLA region cannot be
interpreted in isolation. Some extended HLA haplotypes
are conserved over several megabases. “A1-B8-DR3” (also
called “8.1”) has almost no variation over nearly 4 Mb of
DNA (18). Consequently, an association study of any
genetic locus within this haplotype must necessarily take
into account the effects of all of the other loci on the
conserved haplotype. Stratifying by other HLA loci has
shown that A*0101, seen more frequently in patients than
in control subjects, is actually protective for type 1 diabe-
tes when LD of A*0101 with the type 1 diabetes–predis-
posing haplotype DRB1*0301-DQA1*0501-DQB1*0201 is
taken into account (7).
In some cases, effects of alleles that appear type 1
diabetes associated, even after adjustment of the data for
LD with DR-DQ haplotypes can still be misleading. C*1601
appears protective for disease, and the protective effect
persists even after adjustment of the data for LD with
DR-DQ. Closer examination of LD patterns in the data
reveal that C*1601 is in strong LD with B*4403, which also
appears strongly type 1 diabetes protective. Examination
of this large dataset allowed the observation that the
apparent type 1 diabetes effect for C*1601 can be ex-
plained by its LD to B*4403, but the B*4403 allele appears
protective in the absence of C*1601. Given the function of
HLA class II antigens, the B*4403 allele itself seems a likely
candidate for a causative allele, although the formal pos-
sibility remains that the disease protection may come from
an unidentiﬁed allele at a locus in LD with B*4403.
Unraveling susceptibility for other HLA class I allele
combinations will require even larger datasets than the
current one.
In the data reported here, the additional predisposing
effect of the B*3906 allele was apparent on all predisposing
haplotypes examined (DR3, DR4, DR1, DR8), strongly
suggesting that the predisposing effect may be due to
TABLE 5
Summary of statistically signiﬁcant relative ORs on speciﬁc haplotypes for class I alleles
Allele DR3 DR4 DR8 DR1 DR2 Number
Consistent
effect
A*0101 0.69 (0.59–0.78) 0.75 (0.57–0.98) 2 Yes
A*0201 0.58 (0.38–0.89)
A*0301 1.47 (1.14–1.88)
A*1101 X 0.60 (0.38–0.91)
A*2402 1.69 (1.25–2.28) 1.52 (1.15–2.01) 3.31 (1.90–5.74) 2.18 (1.51–3.14) 4 Yes
A*2601 0.65 (0.46–0.89) X
A*2902 2.22 (1.03–4.78)
A*3101 0.57 (0.41–0.79)
A*3201 0.57 (0.36–0.88) 0.19 (0.04–0.89) X 2 Yes
A*6601 X 0.10 (0.01–0.98)
A*6801 0.62 (0.38–0.99) 3.32 (1.14–9.64) 4.83 (1.02–22.6) 3 No
B*0801 0.68 (0.62–0.74)
B*1801 1.58 (1.31–1.90) 1.74 (1.19–2.53) 2 Yes
B*3501 X 4.79 (1.07–21.4) 4.79 (1.07–21.4) 2 No
B*3503 X X 14.54 (2.66–79.3)
B*3801 X 0.70 (0.49–0.97) X
B*3901 X X 2.44 (1.01–5.88)
B*3906 11.56 (0.68–195.0)† 2.70 (1.16–6.29) 14.03 (5.55–35.4) 7.15 (3.89–13.1) 14.54 (2.66–79.3) 4 Yes
B*4001 0.71 (0.56–0.88)
B*4402 0.34 (0.13–0.84)
B*4403 4.83 (1.12–20.6) 0.5 (0.32–0.77) X X 2 No
B*4901 X 1.61 (1.01–2.53) X X X
B*5001 1.95 (1.22–3.11) X X X
B*5101 0.36 (0.13–0.96)
B*5301 X X X X 28.11 (1.75–449.0)
B*5601 0.10 (0.01–0.81) XXXX
C*0102 0.30 (0.11–0.77)
C*0401 4.82 (1.87–12.3)
C*0501 1.48 (1.21–1.81) 0.29 (0.12–0.68) 2 No
C*0602 1.56 (1.09–2.21) X
C*0701 0.70 (0.60–0.80) 0.26 (0.08–0.80) 0.51 (0.28–0.92) 3 Yes
C*0702 1.31 (1.00–1.70) 3.65 (2.42–5.48) 1.94 (1.41–2.65) 3 Yes
C*1202 X 0.15 (0.03–0.61) X X X
C*1402 X 0.33 (0.11–0.92) X
C*1502 0.57 (0.37–0.87) X
C*1604 X 0.38 (0.15–0.90)
For each allele, the relative OR value represents a comparison of the DR haplotype carrying the allele to that DR haplotype carrying any class
I allele. X  total n in contingency table 12. †Although the conﬁdence interval overlaps 1, this result, with relative OR of 11.56, has been
included for comparison. Data for seven alleles that exhibit a consistent disease association on more than one haplotype are indicated in
boldface type.
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causative allele at another locus in LD with B*3906 must
be present on all haplotypes tested, is possible but seems
unlikely. Other alleles had inconsistent effects across
haplotypes, for example, A*6801 is protective in the con-
text of DR3 haplotypes but predisposing in the context of
DR1 and DR2 haplotypes, suggesting that these effects are
not due to A*6801 but to alleles at other loci on the
haplotypes.
The two strongest type 1 diabetes susceptibility effects
observed in these data are the predisposing effect of
B*3906 and the protective effect of B*5701. Both have been
noted in other class I type 1 diabetes association studies.
B*5701 has also been reported to be associated with
restriction of virus replication in long-term progressors
(19,20). B*5701 is strongly associated with adverse drug
reaction (allergic hypersensitivity) to the nucleoside re-
verse transcriptase inhibitor abacavir, used to treat HIV-
positive patients, leading to implementation of genetic
screening programs to reduce the frequency of allergic
hypersensitive responses.
In summary, the extreme polymorphism of the HLA
class I alleles and the strong LD in the HLA region make
association analysis difﬁcult for individual alleles. The
large size of the T1DGC dataset and the consistent geno-
typing resolution of the samples from the collection allow
meaningful analyses to assess the contribution of classical
HLA alleles to type 1 diabetes susceptibility. The data
presented here argue that HLA class I alleles (minimally
B*3906 and B*5701) should be considered for inclusion in
type 1 diabetes genetic screening panels. Thorough under-
standing of the risk of individual HLA alleles will provide
clues to biological mechanism of type 1 diabetes patho-
genesis and, eventually, could lead to intervention or
prevention targets. The results presented here represent a
step toward this goal.
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